
Zenotech Laboratories Gears Up for Q3 Reveal on 23rd January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 22 Jan 2026 • 4:01 pm
Posted by:

Zenotech Laboratories' Q3 results FY26 are scheduled to be announced on 23rd January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Zenotech Laboratories Q3 Results 2026 Preview
- Zenotech Laboratories' revenue is expected to be in the range of ₹11.24 crore, a 15.11% YoY increase.
- Profit After Tax, or PAT, is projected to rise by 25.63% YoY.
- Zenotech Laboratories' EBITDA is expected to rise to ₹2.73 crore.
- Net profit is ₹1.69 crore, up 25.63% YoY
Zenotech Laboratories Share Performance
- Over the past six months, Zenotech Laboratories' share price has fallen by 24.62% to ₹46.65.
- Moreover, over the past year, the stock has decreased by 25.40%.
- Despite this weak short-term performance, Zenotech Laboratories' stock has delivered a financially sound 51.22% return over the past 5 years.
- As of 22nd January 2026, the stock traded at ₹46.65 per share.
Key Factors to Watch for Zenotech Laboratories Q3 Results FY26
- Revenue Trend: Whether net sales have grown or declined compared with recent quarters, given volatility in past quarterly sales.
- Profitability Movement: Change in PAT — improvement, stability or further losses — as the company has swung between profits and losses recently.
- Operating Margins: Trends in gross and operating margins, since margin compression has been a recent concern.
- Cost & Expense Control: How well the company is managing costs like employee and production expenses vis-à-vis revenue performance.
- Balance Sheet & Cash Position: Liquidity or net cash status, important for a small, niche injectable player with limited scale.
Final Thoughts
Zenotech Laboratories will announce its Q3 FY26 results on 23rd January 2026. Analysts expect 15.11% YoY revenue growth, a 25.63% rise in PAT, and an 36.31% rise in EBITDA. Zenotech Laboratories focuses on developing and manufacturing specialty generic pharmaceutical injectables, particularly for oncology, biotechnology and anesthesiology applications, offering contract manufacturing and recombinant protein services with an emphasis on high-quality biotherapeutic and niche therapy products.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026
Best Stocks to Buy Today: Explore Best Stocks With Expected Trends
Milky Mist Dairy Foods IPO Details: Everything You Should Know about
Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?
Taurian MPS IPO GMP & Review: Should You Apply or Avoid?
Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?
Dev Accelerator IPO GMP & Review: Apply or Avoid?
Recent Articles

Kalyan Jewellers Share Price Rally: Stock Gains About 42% in 11 Sessions After Rs 427 Crore Q2 Profit, Hits Near Two-Year High and Trades at Rs 708.15 on 16 November 2026 as UBS and Jefferies Raise Targets
16 November 2026

Tata Motors PV vs Eicher Motors After Q2: TMPV Falls 8.7% to Rs 262 on a Rs 5,451 Crore Loss and JLR Guidance Cut While Eicher Posts Record Revenue and a 15% Profit Rise
16 November 2026

Belrise Industries Share Price Jumps 9% to Rs 235 After Q2 PAT Rises 25%: Fresh H-One India Merger, Electronics Entry and Aerospace Orders Drive a Spike of up to 12.4% on 16 November 2026
16 November 2026

Sebi Trading Terminal Rules: What Biometrics, Geotagging and MAC Address Mapping Could Mean for Brokers, Authorised Persons and Traders as the Regulator Targets Terminal Misuse
16 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Kalyan Jewellers Share Price Rally: Stock Gains About 42% in 11 Sessions After Rs 427 Crore Q2 Profit, Hits Near Two-Year High and Trades at Rs 708.15 on 16 November 2026 as UBS and Jefferies Raise Targets
Tata Motors PV vs Eicher Motors After Q2: TMPV Falls 8.7% to Rs 262 on a Rs 5,451 Crore Loss and JLR Guidance Cut While Eicher Posts Record Revenue and a 15% Profit Rise
Belrise Industries Share Price Jumps 9% to Rs 235 After Q2 PAT Rises 25%: Fresh H-One India Merger, Electronics Entry and Aerospace Orders Drive a Spike of up to 12.4% on 16 November 2026
Sebi Trading Terminal Rules: What Biometrics, Geotagging and MAC Address Mapping Could Mean for Brokers, Authorised Persons and Traders as the Regulator Targets Terminal Misuse
Ola Electric vs Ather Energy After Q2: Ather's Rs 1.26 Crore Profit and 63% Revenue Growth Against Ola's Rs 362 Crore Loss and 39% Revenue Fall, and What the Share Prices Imply on 16 November 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





